Full-Time

Scientist II

Drug Product

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Compensation Overview

$128k - $160k/yr

Mid, Senior

San Carlos, CA, USA

This position is hybrid, requiring some in-office days at the headquarters in Redwood City, CA.

Category
Lab & Research
Medical Research
Requirements
  • A graduate degree in Pharmaceutical Science, Chemistry, Chemical Engineering, or related field is desirable.
  • Preferably MS with 5+ years or PhD with 2+ years of experience in the pharmaceutical/biotech industry with drug product development and manufacturing experience of small molecules.
  • Experience in formulation and process development, DOE study, technology transfer, process scale-up, clinical manufacturing and primary packaging of solid oral drug products.
  • Familiar with pharmaceutical analytical techniques to support drug product development and manufacturing.
  • Knowledge and understanding of current ICH guidelines, GMP regulations, quality systems, and related industry practices for pharmaceutical development.
  • Working experience in managing development and manufacturing activities at CDMOs.
  • Excellent communication (both verbal and technical) and problem-solving skills.
  • Ability to multi-task and thrive in a fast-paced innovative environment.
Responsibilities
  • Support drug product development and manufacturing activities to advance new chemical entities (NCEs) from clinical development to commercialization.
  • Support and/or lead formulation and process development, clinical manufacturing, scale-up, technology transfer, process validation and packaging of solid oral drug products at CDMOs.
  • Manage GMP manufacturing of drug products to support clinical studies, stability, and process validation, including production timeline, raw materials inventory, etc.
  • Prepare, review, and approve manufacturing batch records, campaign reports, development study protocols and reports. Perform data review of batch records and summarize batch production history. Assist preparation of CMC regulatory submission documents.
  • Support and manage process development studies using a quality-by-design approach. Study and identify critical quality attributes and critical process parameters for drug product. Explore and establish proven acceptable range and control strategy for drug product manufacturing.
  • Collaborate with cross-functional teams, including but not limited to Clinical Supply, Quality Assurance, Analytical Development and QC, Drug Substance, Project Management, Regulatory Affairs, and Research team, to achieve project goals in a timely manner.
  • Travel to CRO/CDMO sites for the oversight of development and manufacturing activities (up to 10%).
Desired Qualifications
  • Experience in enabling formulation development, spray dried dispersion, roller compaction, tablet compression, and coating are preferred.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to concentrate their research and development efforts in this niche area. Their goal is to improve cancer treatment outcomes for patients with RAS mutations by providing effective targeted therapies.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in net cash for R&D.
  • FDA fast-tracking RAS-targeted therapies supports their pipeline development.
  • Increased interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and timelines.
  • EQRx's pricing model may conflict with Revolution Medicines' strategies.
  • $600M public stock offering may dilute existing shareholder value.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

11%
Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

RevMed
Feb 21st, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Revolution Medicines

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within

Seeking Alpha
Feb 14th, 2024
Corvex Management buys Illumina, exits Apple, TKO

Corvex Management buys Illumina, exits Apple, TKO.

GlobeNewswire
Nov 1st, 2023
Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Revolution Medicines Stockholders Vote “For” Proposed Acquisition Of Eqrx, Inc.

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders

PharmaSources
Aug 15th, 2023
EQRx, known as the "TEMU" of the Pharmaceutical Industry, has been Acquired by Revolution Medicines

On August 1st, EQRx announced an agreement with Revolution Medicines to be acquired in an all-stock transaction, which is expected to be completed in November 2023.